How Rimegepant Works
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP receptors to prevent migraine pain signaling. 1
Mechanism of Action
Rimegepant functions by antagonizing the CGRP receptor, a key target in migraine pathophysiology 1. CGRP is a vasodilatory neuropeptide centrally involved in migraine attacks 2. By blocking CGRP receptors with high affinity, rimegepant interrupts the pain signaling cascade without causing vasoconstriction in coronary or intracranial arteries 3.
Key Pharmacologic Properties
Absorption and Onset:
- Rapidly absorbed with maximum concentration reached at 1.5 hours post-dose 1
- Absolute oral bioavailability of approximately 64% 1
- This rapid absorption profile supports its effectiveness for acute migraine treatment 3
Distribution and Metabolism:
- Volume of distribution: 120 L 1
- Plasma protein binding: approximately 96% 1
- Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9 1
- Elimination half-life: approximately 11 hours, which supports sustained efficacy for preventive use 1, 3
Excretion:
- 78% recovered in feces, 24% in urine 1
- Unchanged rimegepant is the major component in both feces (42%) and urine (51%) 1
Clinical Significance
Unlike triptans, rimegepant does not induce vasoconstriction, making it appropriate for patients with cardiovascular disease or contraindications to vasoconstrictive medications 3, 2. The drug can be safely co-administered with triptans without clinically meaningful blood pressure elevation or pharmacokinetic interactions 3.
Important caveat: While the exact relationship between rimegepant's pharmacodynamic activity and its clinical effects remains unknown 1, its dual approval for both acute and preventive migraine treatment reflects its sustained receptor antagonism over time.
The orally disintegrating tablet formulation offers convenience and potentially faster response compared to conventional tablets, particularly beneficial for patients experiencing nausea during migraine attacks 4.